Due to the importance of the MAPK pathway in melanoma, the first targeted therapies were small-molecule inhibitors of BRAF (vemurafenib, dabrafenib), which were followed by combination therapies with BRAF and MEK inhibitors [5]. Here, BRAF is linked to melanoma.